SUMMIT European Cannabis Insights Summit 2026 — Exclusive industry intelligence Register Now
EVENT Cannabis Europa London 2026 — Europe's cannabis industry unites Get Tickets

Recent Searches

    Curaleaf Makes Application For TSX Listing

    By

    This Nov 3rd, join us for the third edition of Business of Cannabis: New York at The Williamsburg Hotel. A day long leadership summit focused on retail, investment & policy across New York and North America. Tickets on-sale now – www.cannabisnewyork.live

    Curaleaf Holdings has confirmed it has filed its application to list its subordinate voting shares on the Toronto Stock Exchange (TSX).

    Curaleaf announced its intentions to list on the TSX in May 2023, Curaleaf has now confirmed it aims to list subordinate voting shares.

    The move aims to expand the company’s investor base, and Curaleaf stated in July that it “wishes to implement a reorganisation of its U.S. cannabis assets”, exploring a number of different ways it could implement the reorganisation in order to achieve the listing.

    Curaleaf needed the consent of its shareholders before listing, and previously announced that it had completed a marketed offering of subordinate voting shares on October 3, 2023 in order to satisfy a condition required for a potential listing on the TSX.

    Executive Chairman Boris Jordan, stated: “We are pleased to announce we have submitted our listing application to the TSX.

    “I believe uplisting to the TSX will provide greater access to a broader set of global institutional investors, offer custody solutions backed by U.S. financial institutions, reduce volatility in our stock by having dedicated market makers, and make Curaleaf available for inclusion into indexes such as TSX and MSCI, all to the benefit of our stakeholders.

    “We continually manage the business with the best interest of the company in mind, and filing our application with the TSX is yet another step in that direction.”

    The company has confirmed that the listing of its subordinate voting shares on the TSX remains subject to the review of the TSX and is contingent on the satisfaction of all listing and regulatory requirements.

    Stephanie Price

    Stephanie is a journalist for Business of Cannabis, writing about science, research, policy and industry developments in cannabis, CBD and psychedelics. In 2013 Stephanie gained her BA in English and Media, focusing on journalism and propaganda, where her magazine ‘Game Theory’ focused on developments and disruptors over the coming decade including cannabis, psychedelics, blockchain/crypto and free speech. In 2015 Stephanie received her National Council for the Training of Journalists (NCTJ) diploma whilst working as a reporter in North Wales. Stephanie has a specialism in Medical Cannabis: The Health Effects of THC and CBD through the University of Colorado, and a certificate from the Medical Cannabis Clinicians Society on “Medical Cannabis Explained”.